$BKKT

Alexander Karen sold $15K of BKKT

Alexander Karen (Chief Financial Officer) sold 1,907 shares of Bakkt, Inc. (BKKT) at $7.93 on 2026-06-25.

Original reporting
SEC EDGAR · Alexander Karen
Published Jun 29, 2026, 10:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 10:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BKKT
Neutral
medium confidence
Mentioned
$BKKT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BKKTNeutralLow
01

Why it matters

The disclosure updates insider activity records; it can influence short-term sentiment but does not provide new fundamentals (no guidance, contracts, or regulatory actions).

02

Market read

Traders may monitor BKKT for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

The article lacks context on total compensation, prior sale cadence, and whether the sale was tax-related; also no 10b5-1 plan is cited, which can change how traders interpret intent.

Relevance 3/10Novelty 5/10Timing: new Form 4 filed 2026-06-29 (covers sale dated 2026-06-25)

Background

This is an SEC Form 4 insider transaction disclosure for Bakkt, Inc. (BKKT).

Company-level read

Ticker impact

$BKKTNeutralMedium confidence
Context

CFO Alexander Karen filed a Form 4 open-market sale of 1,907 BKKT shares at $7.93 on 2026-06-25.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless followed by additional disclosures.

Evidence & confidence

The filing is a direct open-market sale with no 10b5-1 plan stated, but the article provides no earnings, guidance, or operational change—so the information is mostly sentiment/positioning related.

Market effects

Minimal; insider sale does not indicate sector-wide change.

None indicated.

None indicated.

Counterpoint

Insider sales are often diversification or liquidity-driven and may not reflect negative company outlook, especially without any accompanying negative operational news.

Key entities

  • Bakkt, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Alexander Karen

    Chief Financial Officer who sold shares via an open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BKKTMedAI 8/10

Bakkt (BKKT) Q2 2026 Earnings Call Transcript

Bakkt (BKKT) reported Q2 2026 revenue of $170.1 million, down 70% from $568.1 million, citing client transitions and weaker digital asset trading volumes. GAAP net income was $80.8 million, driven mainly by a $98.5 million non-cash gain from Transchem warrants. Total transacting volume was $168.8 million; management reiterated an EBITDA breakeven target in Q4 2026.

$BKKTMed

Bakkt Inc (BKKT) (Q2 2026) Earnings Call Highlights: Strong GAAP Net Income

Bakkt’s CEO Akshay Naheta said the company expects adjusted EBITDA break-even in Q4 2026, without a specific date, citing execution and client activations. Management discussed take rates, cross-border margins, and reaffirmed a 2026 TTV target of about $2.5 billion. The firm outlined post-DTR acquisition progress and Bakkt Agent MAU target of ~25,000 by year-end 2026.

$BKKTMed

Bakkt, Inc. (BKKT): Results of Operations and Financial Condition

Bakkt, Inc. (BKKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Bakkt Reports Second Quarter 2026 Results - GAAP net income of $80.8 million, or $1.96 per basic and $1.94 per diluted share - Six commercial offerings live across Bakkt Markets; Total Transacting Volume (“TTV”) of $168.8 million in Q2, including payments volume generated on acqu